The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CYTK | +48.23% | +216.26% | +25.89% | -34% |
| S&P | +20.78% | +72.15% | +11.48% | +509% |
Cytokinetics is a biopharmaceutical company focused on developing small-molecule therapeutics for the treatment of cardiovascular diseases and cancer.
This biopharma company advancing cardiac drug candidates disclosed a notable insider sale amid late-stage clinical development.
B. Lynne Parshall sold $323,650 worth of Cytokinetics shares in November.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $17.76M | 4.9% |
| Gross Profit | $14.89M | 2.4% |
| Gross Margin | 83.89% | -2.0% |
| Market Cap | $7.77B | 39.9% |
| Market Cap / Employee | $11.54M | 0.0% |
| Employees | 673 | 35.1% |
| Net Income | -$183,031.00K | -22.0% |
| EBITDA | -$175,505.00K | -28.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $125.63M | 31.9% |
| Accounts Receivable | $17.76M | 6.7% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.22B | 61.4% |
| Short Term Debt | $60.29M | 97.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -55.55% | -2.6% |
| Return On Invested Capital | -80.98% | 1.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$148,295.00K | -121.8% |
| Operating Free Cash Flow | -$142,651.00K | -117.6% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -35.09 | -14.79 | -17.83 | -14.89 | -96.26% |
| Price to Sales | 247.81 | 46.03 | 75.61 | 88.36 | -70.61% |
| Price to Tangible Book Value | -35.09 | -14.79 | -17.83 | -14.89 | -96.26% |
| Enterprise Value to EBITDA | -30.10 | -36.12 | -41.60 | -46.60 | 20.92% |
| Total Debt | $791.06M | $858.06M | $1.20B | $1.28B | 62.84% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
